ALNY News Alert Alnylam Pharmaceuticals (ALNY) 93.52 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alnylam Pharmaceuticals (ALNY) 93.52 $ALNY

Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
MCBK: 20.30 (+1.04), ISIS: 59.49 (+1.88), ALNY: 93.52 (+0.97), GILD: 91.29 (+1.84), ASPS: 33.81 (+4.37), ACHN: 13.06 (+1.22), OFLX: 34.45 (unch), RCPT: 122.05 (+4.05), HGSH: 4.60 (-0.06), REXX: 5.17 (-0.17)

Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST

NICK: 14.80 (+0.20), JRJC: 5.81 (-0.11), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), VNDA: 14.69 (+1.11), EPAX: 2.46 (-0.08), FES: 1.19 (-0.01), NQ: 4.32 (-0.36), TECU: 3.59 (-0.14), VRML: 1.81 (+0.15), MYOS: 7.10 (+0.07), PME: 2.00 (+0.10), ESPR: 35.97 (-0.08), ALNY: 93.52 (+0.97), IDSA: 4.52 (-0.18), PRLS: 6.85 (+0.01), ACHN: 13.06 (+1.22), SKYS: 11.05 (-0.95), RCPT: 122.05 (+4.05), AGIO: 109.67 (+2.45)

Alnylam Pharmaceuticals Continues To Post Encouraging Results
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 11:15AM CST

ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), ALXN: 181.96 (+3.09), SNY: 46.35 (+0.50)

Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)

Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D.
Business Wire - Fri Dec 19, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that Laurence Reid, Ph.D., the company's Chief Business Officer, plans to resign from the company, effective December 31, 2014. Dr. Reid will be joining Third Rock Ventures (TRV) as an Entrepreneur-in-Residence, and is expected to become a Chief Executive Officer for a TRV portfolio company in the future. Alnylam will initiate an external search to identify a new Chief Business Officer.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), MRK: 57.46 (+0.25)

Alnylam Elects Michael W. Bonney to Its Board of Directors
Business Wire - Thu Dec 18, 7:01AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the election of Michael W. Bonney to its Board of Directors. Mr. Bonney has served as Chief Executive Officer of Cubist Pharmaceuticals and as a member of its Board of Directors since June 2003. His experience prior to that includes leadership positions in successful biotech and pharmaceutical companies including Biogen Idec and Zeneca Pharmaceuticals (now AstraZeneca).
BIIB: 340.89 (+5.13), ALNY: 93.52 (+0.97)

Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 4:50PM CST
Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic disease and hepatic infectious disease.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50)

Additions/deletions from Nasdaq's Q-50 Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:54AM CST

GLNG: 36.67 (+1.15), MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), NUAN: 14.37 (-0.09), UTHR: 130.22 (+2.40), FSLR: 43.67 (-0.39), QQQ: 104.30 (+0.09), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), MPEL: 24.81 (+0.20), EXPE: 89.01 (+0.09), FFIV: 135.11 (+1.17), SSYS: 81.12 (+0.24), CAR: 64.23 (-0.25), JD: 24.61 (-0.12), SPLK: 61.49 (-0.11), MELI: 127.84 (+1.30), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08)

Quarterly Changes to the NXTQ Index
GlobeNewswire - Mon Dec 15, 6:20AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, December 22, 2014.
MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), EA: 48.06 (+0.23), UTHR: 130.22 (+2.40), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), SSYS: 81.12 (+0.24), FFIV: 135.11 (+1.17), MPEL: 24.81 (+0.20), AAL: 51.43 (+1.22), CAR: 64.23 (-0.25), NWS: 14.92 (-0.07), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08), GLNG: 36.67 (+1.15), NUAN: 14.37 (-0.09), FSLR: 43.67 (-0.39), LRCX: 81.13 (-0.44), EXPE: 89.01 (+0.09), SPLK: 61.49 (-0.11), JD: 24.61 (-0.12), MELI: 127.84 (+1.30), NDAQ: 48.74 (-0.40)

Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user  Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)

Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs"
Business Wire - Fri Dec 12, 6:00AM CST
--Cardio-Metabolic Disease, and Hepatic Infectious Disease STArs -
ALNY: 93.52 (+0.97)

Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
Business Wire - Thu Dec 11, 3:00PM CST
--- First Patient Dosed in ENDEAVOUR will Trigger $25 Million Milestone to Alnylam from Genzyme, a Sanofi Company -
ALNY: 93.52 (+0.97)

Alnylam earns milestone on start of Phase 1 hypercholesterolemia trial
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:06AM CST

ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21)

Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Thu Dec 11, 7:01AM CST
--- Companies Expect to Present Initial Clinical Results in Mid-2015 -
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21)

Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 4:20PM CST
Alnylam (ALNY) announced positive early-stage data on ALN-AT3 of up to 57% antithrombin knockdown in initial multi-dose cohorts of hemophilia subjects.
BIIB: 340.89 (+5.13), ALNY: 93.52 (+0.97), ANIP: 55.24 (+1.79), AMGN: 160.67 (+3.15)

Alnylam therapeutic demonstrates effective AT knockdown in hemophilia cohort
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:30AM CST

ALNY: 93.52 (+0.97)

Critical Alerts For MannKind, Merck, Alnylam Pharmaceuticals, Nu Skin Enterprises and Organovo Released By InvestorsObserver
PR Newswire - Tue Dec 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MNKD, MRK, ALNY, NUS and ONVO.
ALNY: 93.52 (+0.97), ONVO: 6.84 (+0.03), NUS: 45.27 (+0.78), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)

Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 6:19AM CST
Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?
ALNY: 93.52 (+0.97)

Alnylam Reports Positive Initial Results for ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders, from Ongoing Phase 1 Trial
Business Wire - Mon Dec 08, 8:15PM CST
--- Subcutaneous Dose Administration of ALN-AT3 Found to be Well Tolerated in Healthy Volunteers and Initial Cohorts of Hemophilia Subjects -
ALNY: 93.52 (+0.97)

Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases
Business Wire - Sun Dec 07, 9:10AM CST
--- New Pre-Clinical Data Presented at American Society of Hematology (ASH) Meeting, Including Results Showing Robust C5 Knockdown of up to 99.2% and Inhibition of Serum Hemolytic Activity of up to 96.2% in Non-Human Primates for over Seven Months -
ALNY: 93.52 (+0.97)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Fortune Brands' Strategic Moves for Growth and Innovation

Updated Category News Views 506

Fortune Brands Embraces Change for Future Growth Fortune Brands Innovations, Inc. (NYSE: FBIN), a leading innovation company committed to transforming spaces into havens, has announced pivotal changes aimed at enhancing its growth opportunities. These strategic moves reflect the company's dedication to innovation and efficiency as it positions itself for future success....

Continue Reading
Robert Webb's Insightful Stock Options Exercise at NHI

Updated Category News Views 97

Robert Webb Exercises Stock Options at National Health Investors Recently, an important SEC filing revealed that Robert Webb, a Board Member at National Health Investors (NHI), has exercised a significant number of stock options. Key Highlights: The latest Form 4 filing shows that Webb exercised stock options for 70,000 shares of NHI, amounting to a remarkable $1,585,550....

Continue Reading
Palantir Technologies Inc. Increases Investment in UK Defense

Updated Category News Views 271

Palantir Technologies Inc. Stock Update Recently, shares of Palantir Technologies Inc. (NASDAQ: PLTR) saw an increase of 1.58% in pre-market trading following the announcement of a substantial deal with the U.K. government. Strategic Investment in UK Defense This exciting new partnership involves Palantir committing up to £1.5 billion, equivalent to approximately $2...

Continue Reading
Investigation of Varonis Systems, Inc.: A Call to Investors

Updated Category News Views 165

Investigation into Varonis Systems, Inc. Edelson Lechtzin LLP, a well-respected national law firm, is actively investigating Varonis Systems, Inc. (NASDAQ: VRNS) due to potential violations of federal securities laws. This investigation arises from troubling allegations regarding the company's financial disclosures and communication with investors. Varonis Systems,...

Continue Reading
Error Notification on NAV Values in Wealth Invest Fund

Updated Category News Views 127

Error Notification Regarding NAV Values Nasdaq Copenhagen A/S Nikolaj Plads 6 1067 København K Important Information The latest update relates to incorrect NAV values published for the I&T Nordiske Aktier Large Cap division (ISIN: DK0061276656) of Investeringsforeningen Wealth Invest during a specific time frame. Details of the NAV Error This error occurred from 09:45 on...

Continue Reading